<DOC>
	<DOC>NCT01097096</DOC>
	<brief_summary>This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.</brief_summary>
	<brief_title>Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Male and/or female patients below 85 years of age (inclusive) Diagnosis of mild Alzheimer's Disease MiniMental State Examination (MMSE) 20 to 26 (inclusive) at screening, untreated or on stable dose of cholinesterase inhibitor or memantine over the last 4 weeks prior to clinical assessments Previously participated in an AD vaccine study and received active treatment History or presence of an active autoimmune disease History or presence of seizure disorder Presence of significant coronary heart disease and/or cerebrovascular disease Presence of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression) Advanced, severe, progressive or unstable disease that might interfere with the safety, tolerability and pharmacodynamic assessments of the patient Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Neurodegenerative diseases</keyword>
	<keyword>Vaccine</keyword>
</DOC>